Physician profile
Sherry Yang
NPI 1295024057
$2,085.87
in general payments reported to CMS, 2019-2025
13 companies · $949 in 2025
The $949 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.90 · 2020: $15.33 · 2021: $70.52 · 2022: $27.91 · 2023: $678 · 2024: $250 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,125 · Food and Beverage: $727 · Travel and Lodging: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,125.00 |
| Food and Beverage | $727.21 |
| Travel and Lodging | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,477.88 | 2021-2025 | Botox |
| Novartis Pharmaceuticals Corporation | $214.27 | 2019-2025 | |
| Ucb, INC. | $143.96 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $81.13 | 2022-2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $60.38 | 2024-2025 | Dupixent |
| Galderma Laboratories, L.P. | $22.28 | 2025 | Nemluvio |
| Pfizer INC. | $18.38 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $18.22 | 2025 | Valchlor |
| Organon LLC | $16.64 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.60 | 2023 | Sotyktu |
| Amgen INC. | $16.13 | 2025 | Otezla |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.